Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Trial Profile

Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Haemophagocytic lymphohistiocytosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Phase changed from 0 to 1.
    • 02 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2017.
    • 17 Nov 2015 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top